The National Institutes of Health awarded $87 million over three years to launch the Standardized Organoid Modeling Center, aiming to accelerate the shift from animal testing towards reproducible organoid-based drug development models. The initiative supports standardized protocols and enhances the reliability of organoid technologies in biopharmaceutical research. This pivotal investment aligns with FDA strategies to modernize testing pipelines and reduce reliance on traditional animal models, improving translational relevance and ethical standards.